Facilitated By

San Antonio Medical Foundation

Efficacy And Safety Of AM-111 As Acute Sudden Sensorineural Hearing Loss Treatment (Assent)

Principal Investigator(s)
Email for information
Funded by
Research Start Date

A Phase III, randomized, double-blind, placebo-controlled, parallel group, multi-center, efficacy and safety trial of AM-111 in the treatment of subjects suffering from idiopathic sudden sensorineural hearing loss.

Drug Discovery
Regenerative Medicine
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.